West Announces Third-Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
West Pharma (WST) Tops Q3 EPS by 8c, Revenues Beat; Raises FY19 EPS/Revenue Guidance Above Consensus
October 24, 2019 6:15 AM EDTWest Pharma (NYSE: WST) reported Q3 EPS of $0.79, $0.08 better than the analyst estimate of $0.71. Revenue for the quarter came in at $456.1 million versus the consensus estimate of $450.94 million.
Third-Quarter 2019 Summary (comparisons to prior-year period)
Net sales of $456.1 million grew 5.7%; organic sales growth was 7.9%; sales from a recent acquisition contributed an additional 20 basis points of growth; currency translation reduced sales by 240 basis points.Reported-diluted EPS of $0.75 increased 3%.Adjusted-diluted EPS of $0.79 increased 4%.Company is raising its full-year 2019 net sales guidance to a new range of between $1.815 billion and $1.825... More